Allan Goldstein - RegeneRx Biopharmaceutica Insider

RegeneRx Biopharmaceuticals Inc -- USA Stock  

USD 0.17  0.025  12.5%

Founder, Chairman, Chief Scientific Advisor and Chairman of Medical and Scientific Advisory Board

Dr. Allan L. Goldstein Ph.D. is Chairman of the Board, Chief Scientific Advisor of the Company. He is Emeritus Professor former Chairman of the Department of Biochemistry and Molecular Medicine at the George Washington University School of Medicine and Health Sciences. Dr. Goldstein is a recognized expert in the field of immunology and protein chemistry, having authored over 435 scientific articles in professional journals. He is also the inventor on over 25 issued andor pending patents in biochemistry, immunology, cardiology, cancer and wound healing. Dr. Goldstein discovered several important compounds, including Ta1, which is marketed worldwide, and Tb4, which is the basis for RegeneRxs clinical program. Dr. Goldstein served on the Board of Trustees of the Sabin Vaccine Institute from 2000 to 2012 and on the Board of Directors of the Richard B. and Lynne V. Cheney Cardiovascular Institute from 2006 to 2012
Age: 77  Chairman Since 1982      
Goldstein has also done pioneering work in the area of medical education, developing distance learning programs for the internet entitled ?Frontiers in Medicine, ? a medical education series that Dr. Goldstein developed. The Board believes that Dr. Goldstein?s scientific expertise, industry background and prior experience as our founder all position him to make an effective contribution to the medical and scientific understanding of the Board, which the committee believes to be particularly important as we continue our Tb4 development efforts.

Management Efficiency

The company has return on total asset (ROA) of (91.17) % which means that it has lost $91.17 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.5) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 872.93 K in liabilities. RegeneRx Biopharmaceuticals Inc has Current Ratio of 0.39 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.

Similar Executives

Entity Summary

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. RegeneRx Biopharmaceuticals Inc (RGRX) is traded on OTC Market in USA. It is located in RegeneRx Biopharmaceuticals, Inc.Rockville, MD and employs 3 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add RegeneRx Biopharmaceuticals Inc to your portfolio

Top Management

RegeneRx Biopharmaceutica Leadership Team
J Finkelstein, CEO
Don Elsey, Director
Allan Goldstein, Chairman
R Elsey, Director
Joseph McNay, Director, MBA
Raymond Elsey, Director
Mauro Bove, Director

Stock Performance

RegeneRx Biopharmaceutica Performance Indicators